Randomized Phase III Trial of Induction Chemotherapy With Docetaxel, Cisplatin, and Fluorouracil Followed by Surgery Versus Up-Front Surgery in Locally Advanced Resectable Oral Squamous Cell Carcinoma
Journal of Clinical Oncology2012Vol. 31(6), pp. 744–751
Citations Over TimeTop 1% of 2012 papers
Lai-ping Zhong, Chen-ping Zhang, Guo-xin Ren, Wei Guo, William N. William, Jian Sun, Han-guang Zhu, Wen-yong Tu, Jiang LI, Yi-li Cai, Li-zhen Wang, Xin-dong Fan, Zhong-he Wang, Yong-jie Hu, Tong Ji, Wen-jun Yang, Weimin Ye, Jun Li, Yue He, Yan-an Wang, Li-Qun Xu, Bo-song Wang, Merrill S. Kies, J. Jack Lee, Jeffrey N. Myers, Zhiyuan Zhang
Abstract
Our study failed to demonstrate that TPF induction chemotherapy improves survival compared with up-front surgery in patients with resectable stage III or IVA OSCC.
Related Papers
- Docetaxel (Taxotere): preclinical and general clinical information.(1999)
- → Ototoxicity in patients with invasive ductal breast cancer who were treated with docetaxel: report of two cases(2020)12 cited
- → The plinabulin/docetaxel combination to mitigate the known safety concerns of docetaxel.(2016)3 cited
- → Docetaxel (Taxotere) in the Treatment of Non-Small Cell Lung Cancer(2002)18 cited
- TS-1 による術後補助療法中に発症しWeekly Docetaxel 療法により著効をみた胃癌腹膜播種の1 例(2005)